Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Valeant Pharmaceuticals International Inc. (T.BHC) had Normalized Income after Taxes of -1.96B for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
-1.95B |
|
-- |
|
-- |
|
-- |
|
-1.30B |
|
-- |
|
-1.86B |
|
-1.86B |
|
-1.96B |
|
-1.96B |
|
-1.96B |
|
|
Normalized Income after Taxes |
-1.96B |
-1.30B |
|
-879.52M |
|
372.80M |
|
372.80M |
|
-5.24 |
|
-5.24 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
33.61B |
|
-- |
|
-- |
|
-- |
|
35.10B |
|
-1.48B |
|
-20.98B |
|
-1.48B |
|
373.50M |
|
| Cash Flow Statement Financials | |
315.58M |
|
-190.72M |
|
-137.21M |
|
1.82B |
|
1.80B |
|
-17.84M |
|
71.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.32 |
|
-- |
|
-- |
|
1.06 |
|
-19.22 |
|
70.76% |
|
-37.64% |
|
-37.64% |
|
-- |
|
-53.65% |
|
-56.38% |
|
170.14M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.46 |
|
1.15 |
|
78.13 |
|
132.26% |
|
9.36% |
|
-5.84% |
|
-7.61% |
|
-3.97 |
|
0.46 |
|
0.85 |
|